Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BDSX 
Biodesix Inc (BDSX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: BDSX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $32.5
1 Year Target Price $32.5
| 4 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -66.58% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 51.36M USD | Price to earnings Ratio - | 1Y Target Price 32.5 |
Price to earnings Ratio - | 1Y Target Price 32.5 | ||
Volume (30-day avg) 6 | Beta 0.98 | 52 Weeks Range 3.44 - 34.40 | Updated Date 10/19/2025 |
52 Weeks Range 3.44 - 34.40 | Updated Date 10/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.2 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -53.66% | Operating Margin (TTM) -48.42% |
Management Effectiveness
Return on Assets (TTM) -20.81% | Return on Equity (TTM) -219.68% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 113013000 | Price to Sales(TTM) 0.67 |
Enterprise Value 113013000 | Price to Sales(TTM) 0.67 | ||
Enterprise Value to Revenue 1.48 | Enterprise Value to EBITDA -2.72 | Shares Outstanding 8000000 | Shares Floating 3040223 |
Shares Outstanding 8000000 | Shares Floating 3040223 | ||
Percent Insiders 56.72 | Percent Institutions 24.31 |
Upturn AI SWOT
Biodesix Inc
Company Overview
History and Background
Biodesix, Inc. was founded in 2005 and is a molecular diagnostics company focused on lung disease. They aim to personalize medicine by providing actionable genomic and proteomic information that empowers physicians to make more informed treatment decisions.
Core Business Areas
- Lung Diagnostic Tests: Biodesix offers a portfolio of non-invasive blood-based diagnostic tests for lung cancer and other lung diseases. These tests help guide treatment decisions by providing information about prognosis, therapy selection, and monitoring disease progression.
Leadership and Structure
The leadership team consists of experienced professionals in diagnostics, oncology, and business management. The organizational structure typically includes departments for research and development, commercial operations, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- Nodify XL2: A blood-based test designed to help physicians rule out lung cancer in patients with indeterminate lung nodules. Market share data is not publicly available. Competitors include Veracyte and various imaging techniques.
- LungStrat Dx Lung Cancer Test: A blood-based test designed to help physicians determine the prognosis of lung cancer in patients. The competitive market includes other diagnostic companies and genomic testing providers. Revenue data is not publicly available.
- GeneStrat NGS: A comprehensive genomic profiling test used to identify actionable mutations in lung cancer patients, which informs targeted therapy selection. Competitors include Foundation Medicine and Guardant Health. Revenue data is not publicly available.
Market Dynamics
Industry Overview
The molecular diagnostics industry is growing rapidly, driven by increasing demand for personalized medicine and advancements in genomic technologies. The lung cancer diagnostics segment is particularly competitive due to the high incidence and mortality rates of the disease.
Positioning
Biodesix positions itself as a leader in lung cancer diagnostics, leveraging its proprietary technologies and expertise to provide clinically valuable information to physicians. Their focus on non-invasive blood-based tests differentiates them from companies offering tissue-based assays.
Total Addressable Market (TAM)
The total addressable market for lung cancer diagnostics is estimated to be billions of dollars annually. Biodesix is positioned to capture a portion of this market through its innovative products and strategic partnerships. The TAM is expansive as there are many applications ranging from screening to diagnosis to treatment decisions.
Upturn SWOT Analysis
Strengths
- Proprietary technology platform
- Focus on non-invasive blood-based tests
- Strong relationships with key opinion leaders
- Portfolio of diagnostic tests for lung cancer
Weaknesses
- Limited market share compared to larger competitors
- Reliance on reimbursement approvals
- High research and development costs
- Cash burn
Opportunities
- Expanding into new markets and geographies
- Developing new diagnostic tests for other cancers
- Collaborating with pharmaceutical companies
- Increasing adoption of personalized medicine
Threats
- Competition from larger diagnostic companies
- Changes in reimbursement policies
- Technological advancements by competitors
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- Veracyte (VCYT)
- Exact Sciences (EXAS)
- Guardant Health (GH)
Competitive Landscape
Biodesix faces intense competition from established diagnostic companies with larger market shares and greater resources. Biodesix's competitive advantage lies in its focus on lung cancer and its proprietary technology platform.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is reported within SEC filings.
Future Projections: Future projections are based on analyst estimates found from financial analysis reports.
Recent Initiatives: Recent initiatives include the launch of new diagnostic tests and strategic partnerships.
Summary
Biodesix is a molecular diagnostics company focused on lung disease, offering non-invasive blood-based tests. It faces strong competition in a rapidly growing market. Their innovation helps them stand out. The company faces challenges with cash flow and competition, but has opportunities for growth through market expansion and new product development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q), Company Website, Press Releases, Financial News Outlets, Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is approximate and based on available sources. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biodesix Inc
Exchange NASDAQ | Headquaters Louisville, CO, United States | ||
IPO Launch date 2020-10-28 | President, CEO & Director Mr. Scott Hutton | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 273 | Website https://www.biodesix.com |
Full time employees 273 | Website https://www.biodesix.com | ||
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development, and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.